United Therapeutics CFO exercises, sells 10k shares
UNITED THERAPEUTICS Corp CFO James Edgemond exercised and sold shares in a planned transaction.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
UNITED THERAPEUTICS Corp CFO James Edgemond exercised and sold shares in a planned transaction. On April 30, 2026, he exercised 10,000 stock options for Common Stock at a strike price of $135.42 per share and then sold 10,000 shares in a series of open-market trades at prices reported between $569.24 and $578.76 per share.
These actions were made under a Rule 10b5-1 trading plan entered into on October 31, 2025. After the transactions, he directly owned 18,876 shares of United Therapeutics common stock.
Insider Trade Summary 10b5-1
Exercise and Sale: 10,000 shares ($4.37M approx. pre-tax spread)
Exercise and Sale
13 txns
Insider
EDGEMOND JAMES
Role
CFO AND TREASURER
Sold
10,000 shs ($5.73M)
Approx. gross sale proceeds
$5.73M
Approx. exercise cost
$1.35M
Approx. pre-tax spread
$4.37M
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option | 10,000 | $0.00 | $0.00 |
| Exercise | Common Stock | 10,000 | $135.42 | $1.35M |
| Sale | Common Stock | 262 | $569.2437 | $149K |
| Sale | Common Stock | 484 | $570.1912 | $276K |
| Sale | Common Stock | 2,940 | $571.2313 | $1.68M |
| Sale | Common Stock | 3,034 | $572.0028 | $1.74M |
| Sale | Common Stock | 880 | $573.0046 | $504K |
| Sale | Common Stock | 887 | $574.0653 | $509K |
| Sale | Common Stock | 273 | $574.9643 | $157K |
| Sale | Common Stock | 486 | $576.2407 | $280K |
| Sale | Common Stock | 336 | $577.2372 | $194K |
| Sale | Common Stock | 378 | $578.0696 | $219K |
| Sale | Common Stock | 40 | $578.76 | $23K |
Holdings After Transaction:
Stock Option — 42,500 contracts (Direct);
Common Stock — 18,876 shares (Direct)
Footnotes (11)
- F1. This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025.
- F10. This transaction was executed in multiple trades at prices ranging from $576.75 to $577.72. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F11. This transaction was executed in multiple trades at prices ranging from $577.76 to $578.66. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F2. This transaction was executed in multiple trades at prices ranging from $568.58 to $569.48. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F3. This transaction was executed in multiple trades at prices ranging from $569.58 to $570.57. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F4. This transaction was executed in multiple trades at prices ranging from $570.61 to $571.57. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F5. This transaction was executed in multiple trades at prices ranging from $571.61 to $572.60. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F6. This transaction was executed in multiple trades at prices ranging from $572.61 to $573.40. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F7. This transaction was executed in multiple trades at prices ranging from $573.61 to $574.60. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F8. This transaction was executed in multiple trades at prices ranging from $574.61 to $575.57. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F9. This transaction was executed in multiple trades at prices ranging from $575.73 to $576.72. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Key Figures
Options exercised: 10,000 shares
Option strike price: $135.42 per share
Shares sold: 10,000 shares
+5 more
8 metrics
Options exercised
10,000 shares
Stock options for Common Stock exercised on April 30, 2026
Option strike price
<money>$135.42</money> per share
Exercise price for 10,000 stock options
Shares sold
10,000 shares
Common Stock sold in open-market transactions on April 30, 2026
Highest reported sale price
<money>$578.76</money> per share
Weighted average price for one sale tranche
Lowest reported sale price
<money>$569.24</money> per share
Weighted average price for another sale tranche
Shares held after transactions
18,876 shares
Directly owned Common Stock following all reported trades
Rule 10b5-1 plan date
October 31, 2025
Date the trading plan governing these trades was entered into
Option expiration date
March 15, 2027
Expiration date for the exercised stock options
Key Terms
Rule 10b5-1 trading plan, weighted average price, stock options, derivative security, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported above reflects the weighted average price"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
stock options financial
"This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan"
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
derivative security financial
"Exercise or conversion of derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
open-market sale financial
"Sale in open market or private transaction"
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did UNITED THERAPEUTICS (UTHR) CFO James Edgemond report?
CFO James Edgemond reported exercising 10,000 United Therapeutics stock options and selling 10,000 shares of Common Stock. The sales occurred in multiple open-market trades on April 30, 2026, at weighted average prices in the high $560s to high $570s per share.
At what price did the UNITED THERAPEUTICS (UTHR) CFO exercise his stock options?
He exercised 10,000 stock options at a strike price of $135.42 per share. These options converted into 10,000 shares of United Therapeutics Common Stock before being sold in separate open-market transactions disclosed in the same Form 4 filing.
Were the UNITED THERAPEUTICS (UTHR) CFO’s trades part of a Rule 10b5-1 plan?
Yes. The Form 4 footnotes state that the stock option exercise and subsequent sale of shares were executed pursuant to a Rule 10b5-1 trading plan. That plan was entered into by the reporting person on October 31, 2025, indicating the trades were pre-arranged.
What do the weighted average price footnotes mean in the UTHR Form 4?
Several transactions were executed in multiple trades within specified price ranges, so the Form 4 reports a single weighted average price. The footnotes explain this and note the CFO will provide detailed trade counts and prices to the SEC, issuer, or security holders upon request.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates